Journal of Stem Cell Research & Therapy

Does the addition of EPAT to SVF improve the outcomes in severe degenerative joint conditions?

7^th Annual Conference on Stem Cell and Regenerative Medicine

August 04-05, 2016 Manchester, UK

Hazem Barmada

Mississippi Stem Cell Treatment Center, USA

Scientific Tracks Abstracts: J Stem Cell Res Ther

Abstract:

Stromal vascular fraction (SVF) was first isolated from adipose tissue around 1970, but it was not until early this century that its potential in providing regenerative cells for treatment of various medical conditions was realized. SVF has proved very effective in helping manage many hitherto difficult or untreatable conditions, including severe degenerative joint disease (DJD), medically. Nonetheless, it has not been effective in every case, especially in the more severe cases of DJD. Extracorporeal Pulse Activation Technology (EPAT), Alias Dictus Shock or Pressure Wave Therapy (ESWT), is a non-invasive technology platform of Storz Medical that employs acoustic pressure waves to affect a mechanico-transduction response at the cellular level, which leads to cell activation, improved metabolism, angiogenesis, neovascularization and improved healing. This has been used as a stand-alone modality for treating various musculoskeletal conditions in Germany over the past twenty years. In four patients with severe DJD who have either refused surgery or had undergone multiple unsuccessful surgeries, we found the addition of EPAT to the deployment of SVF intravenously and locally, highly effective in decreasing pain, reducing stiffness and increasing functionality.

Biography :

Hazem Barmada is a Cardiovascular and Thoracic Surgeon. He was graduated from St. Andrews and Manchester Universities in 1971 and 1974, respectively. He was active in martial arts in Britain from 1968 to 1984 and was a Medical Officer to the Martial Arts Commission and other major karate organizations in GB from 1974 to 1984. He is a Fellow of the Royal College of Surgeons of Edinburgh in General and Cardiothoracic Surgery, the intercollegiate British Boards in Cardiothoracic Surgery and the Royal Society of Medicine in London and is also a Member of the Society of Thoracic Surgeons and American College of Phlebology. He has two patents and published a number of papers. His interests include regenerative medicine and stem cell research, sports injuries and venous and lymphatic disease.

Email: Barmada@GulfCoastStemCell.com